ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0660

Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0077

Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome

(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0078

Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers

(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0046

Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0072

Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons

(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0556

Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0185

Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation

(0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

9:00AM-11:00AM: Abstract Number: 0718

Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0712

Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0548

Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0635

Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0704

Clinical Characteristics and Outcomes in Patients Found to Have Clinically Isolated Aortitis After Aortic Aneurysm Repair: A Single-Center Experience

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0359

Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0642

Clinical Characteristics of Systemic Sclerosis, Systemic Sclerosis Overlap Syndromes and Systemic Sclerosis-mixed Connective Tissue Disease in an Asia-Pacific Cohort- an APLAR Scleroderma Special Interest Group Study

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0370

Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

«Previous Page
1
…
8
9
10
11
12
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].